Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AL-108 enters phase I trials for Alzheimer's disease

Jan. 31, 2005

GB Therapeutics acquires CHF-1512 for Parkinson's disease

Jan. 31, 2005

New therapies for Parkinson's disease claimed by Roche

Jan. 28, 2005

New opioid analgesics described in a Euroceltique patent

Jan. 28, 2005

Alnylam initiates program to develop RNAi therapeutics for spinal cord injury

Jan. 28, 2005

MT-100 recommended for approval in U.K.

Jan. 28, 2005

Group III mGluRs agonist shows promise in the treatment of neuropathic pain

Jan. 28, 2005

Nociceptin analogues described in patent literature

Jan. 27, 2005

New combinations for the treatment of multiple sclerosis

Jan. 27, 2005

ND-7001 enters phase I

Jan. 27, 2005

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...